Opus Genetics, INC. 8-K Filing
Ticker: IRD · Form: 8-K · Filed: Apr 7, 2026 · CIK: 0001228627
Sentiment: neutral
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2026-04-07 07:01:10
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IRD The Nasdaq
Filing Documents
- ef20069654_8k.htm (8-K) — 28KB
- ef20069654_ex10-1.htm (EX-10.1) — 26KB
- 0001140361-26-013481.txt ( ) — 185KB
- ird-20260401.xsd (EX-101.SCH) — 4KB
- ird-20260401_lab.xml (EX-101.LAB) — 21KB
- ird-20260401_pre.xml (EX-101.PRE) — 16KB
- ef20069654_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 1, 2026, Opus Genetics, Inc. (the "Company") entered into a Change in Control Bonus Payment Agreement with each of Dr. George Magrath, Robert Gagnon, Joseph Schachle, and Dr. Ashwath Jayagopal, its Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and Chief Scientific and Development Officer, respectively (the "Executives"), which provide that the Company will reimburse the Executives for any excise taxes incurred by the Executives in connection with a change in control of the Company under Section 4999 of the Internal Revenue Code of 1986, as amended. The foregoing summary of the Executives' Change in Control Bonus Payment Agreements is qualified by reference to the complete text of the Form of Change in Control Bonus Agreement , a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1* Form of Change in Control Bonus Agreement. 104 Cover Page Interactive Data File (embedded within Inline XBRL document). * Indicates management contract or compensatory plan. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 7, 2026 OPUS GENETICS, INC. By: /s/ Dr. George Magrath Name: Dr. George Magrath Title: Chief Executive Officer